Elevated SLC6A6 expression drives tumorigenesis and affects clinical outcomes in gastric cancer.
CONCLUSION: SLC6A6 may be a potential prognostic marker and therapeutic target. Hypomethylation contributes to SLC6A6 upregulation in gastric cancer.
PMID: 30767502 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Internal Medicine